Accessibility Menu
Cencora logo

Cencora(NYSE) COR

Current Price$300.92
Market Cap$58.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1995)+13,534%
5 Year+161%
1 Year+3%
1 Month+11%
Cencora last closing stock price
MetricPriceDate
Last closeUSD 300.582026-07-22
Cencora stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.35%USD 296.572026-07-15
1 month+10.8%USD 271.282026-06-22
3 month-3.25%USD 310.672026-04-23
Year to date-10.65%USD 336.402025-12-31
1 year+3.37%USD 290.772025-07-22
3 year+60.14%USD 187.692023-07-21
5 year+160.87%USD 115.222021-07-23
Since inception+13,533.83%USD 2.201995-04-04

Cencora Financials at a Glance

Market Cap

$58.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$328.68B

Net Income (TTM)

$2.55B

EPS (TTM)

$13.03

P/E Ratio

23.06

Dividend

$2.35

Beta (Volatility)

0.25 (Low)

Price

$300.92

Volume

0

Open

$306.56

Previous Close

$300.92

Daily Range

$298.79 - $308.54

52-Week Range

$244.82 - $377.54

Estimated Earnings Date

Aug 5, 2026

COR News

scientist lab technician holding wafer

2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now

James HalleyJun 9, 2026
A magnifying glass held over a sheet detailing company finances.

What Is the Fortune 100?

Matt DiLalloNov 19, 2025
People asking questions at a business meeting.

3 Stocks to Buy as the Economy Recovers

David Jagielski, CPAOct 21, 2021
Stethescope and gavel on desk with caduceus ornament and books

Report: States Pushing for $26.4 Billion Settlement With Drug Companies Over Opioid Liability

Eric VolkmanAug 18, 2020
money man holding thousand dollars in hundred bills

Got $1,000? Buy These 3 Medical Distributor Stocks

James HalleyJun 5, 2020
pills spilled out from a bottle

21 States Reject $18 Billion Bid to Settle Opioid Litigation

David Jagielski, CPAFeb 14, 2020
GettyImages-187921657

Should You Own These 3 Healthcare Distributors?

David HaenDec 31, 2019
093 legal settlement

Will a $48 Billion Global Settlement End U.S. Opioid Crisis Lawsuits?

Maxx ChatskoOct 23, 2019
Page 1

COR: Motley Fool Moneyball Superscore

70

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cencora

Cencora delivers medicines and healthcare products to hospitals, pharmacies, and clinics. Its services support both human and animal health providers worldwide.

What’s in the Box? Cencora’s Main Offerings

  • U.S. Healthcare Solutions (constituting approximately 90.6% of revenue for the nine months ended June 30, 2025): Distributes prescription drugs, over-the-counter products, and medical supplies to hospitals, pharmacies, and clinics.
  • Specialty Pharmaceuticals: Provides plasma, vaccines, and high-cost specialty drugs for complex conditions to healthcare providers.
  • Pharmacy Services: Offers pharmacy management, staffing, consulting, and supply management software to healthcare organizations.
  • Animal Health: Supplies medicines, vaccines, and diagnostics for pets and livestock to veterinarians and animal clinics.
  • International Healthcare Solutions (approximately 9% of revenue): Delivers pharmaceuticals and logistics services to pharmacies, hospitals, and health centers outside the U.S.

Growth Moves: Cencora’s Expansion Playbook

  • Acquired Retina Consultants of America in 2025, expanding specialty provider reach.
  • Integrated Alliance Healthcare and PharmaLex in recent years to boost international and consulting services.
  • Entered new global markets through Alliance Healthcare acquisition.
  • Invested in technology and distribution network upgrades since 2023 rebranding to Cencora.

Why Cencora Stands Out (Without the Hype)

Cencora’s global distribution network connects drug makers with healthcare providers efficiently. Its bundled services—like analytics and logistics—help clients manage costs and supply chains. The company’s scale supports reliable delivery and broad product access.

Five Things You Need to Know

  • Revenue was $85.93 billion in QQ1 2026, up 5.5% year-on-year.
  • Gross profit reached $3.07 billion in QQ1 2026, up 35.7% year-on-year.
  • Net income was $560 million in QQ1 2026, up 14.5% year-on-year.
  • Total debt rose to $8.24 billion as of June 30, 2025, mainly from acquisitions.

Bottom Line

Cencora has evolved through acquisitions and service diversification to support healthcare delivery worldwide. Its broad reach and bundled services help it adapt to changing industry needs.

AI Generated • Apr 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

51,000

CEO

Robert P. Mauch, PhD

Website

www.cencora.com

Headquarters

Conshohocken, PA 19428-1800, US

COR Financials

Key Financial Metrics (TTM)

Gross Margin

3.47%

Operating Margin

1.28%

Net Income Margin

0.78%

Return on Equity

115.93%

Return on Capital

29.76%

Return on Assets

3.12%

Earnings Yield

4.34%

Dividend Yield

0.78%

Payout Ratio

18.01%

Stock Overview

Market Cap

$58.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

194.56M

Volume

0

Avg. Volume

1.81M

Financials (TTM)

Gross Profit

$11.40B

Operating Income

$4.20B

EBITDA

$5.00B

Operating Cash Flow

$2.28B

Capital Expenditure

-$718.02M

Free Cash Flow

$1.56B

Cash & ST Invst.

$2.24B

Total Debt

$12.39B

Cencora Performance Analysis

Cencora annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30USD 238,587,006,00011.5%
20232023-09-30USD 262,173,411,0009.9%
20242024-09-30USD 293,958,599,00012.1%
20252025-09-30USD 321,332,819,0009.3%
Cencora sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-06-306.9%
Q42025-09-303.8%
Q12025-12-312.6%
Q22026-03-31-8.8%
Cencora annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30USD 8.048.9%
20232023-09-30USD 8.536.1%
20242024-09-30USD 7.53-11.7%
20252025-09-30USD 7.965.7%
Cencora sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-06-30-4.3%
Q42025-09-30-149.7%
Q12025-12-31264.0%
Q22026-03-31192.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$78.36B

+3.8%

Gross Profit

$3.32B

+27.0%

Gross Margin

4.24%

N/A

Market Cap

$58.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.15M

N/A

Employees

51,000

N/A

Net Income

$1.64B

+128.6%

EBITDA

$2.50B

+89.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$2.24B

+6.0%

Total Debt

$12.39B

+57.7%

Accounts Receivable

$24.89B

+5.0%

Inventory

$20.01B

+5.5%

Long Term Debt

$12.18B

+71.9%

Short Term Debt

$202.66M

-73.7%

Return on Assets

3.12%

N/A

Return on Invested Capital

16.46%

N/A

Free Cash Flow

$1.17B

-63.6%

Operating Cash Flow

$1.34B

-60.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BDXBecton, Dickinson and Company
$153.16-0.44%
PDCOPatterson Companies, Inc.
$31.33-0.90%
MLTOMEDirect Latino, Inc.
$0.00+0.00%
CVETCovetrus, Inc.
$20.99+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About COR

What is the current price of Cencora?

Cencora is trading at $300.92 per share.

What is the 52-week range for Cencora?

Over the past 52 weeks, Cencora has traded between $244.82 and $377.54.

How much debt does Cencora have?

As of the most recent reporting period, Cencora reported total debt of $12.39B.

How much cash does Cencora have on hand?

Cencora reported $2.24B in cash and cash equivalents in its most recent financial results.

What is Cencora’s dividend yield?

Cencora currently has a dividend yield of 0.78%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services